Madam Speaker, thanks to the member opposite for acknowledging that vaccine technology is complicated and that Canadians expect whatever we approve here in Canada, whatever we distribute here in Canada, will go through the utmost rigour in assessing its safety and its effectiveness.
I also want to thank the member opposite for acknowledging that these ultra-cold vaccines use a novel technology, so it is especially new and it is especially important we understand its safety and effectiveness.
In terms of the Emergencies Act in the context of distributing vaccines, at this point I do not think we need to use the Emergencies Act. We are having incredible collaboration with provinces and territories.
In fact, I reject the opposition's assertion that we have not been talking to the provinces and territories. Just this week, we conducted a tabletop exercise with provinces and territories to go through a dry run of what the delivery would look like and assess any kinds of complications. Provinces and territories at all levels, technical tables, medical tables and political tables, have been meeting to talk about vaccine deployment for months and we are very thrilled we are as far along as we are.